WO2003060111A2 - Genes - Google Patents

Genes Download PDF

Info

Publication number
WO2003060111A2
WO2003060111A2 PCT/GB2002/005921 GB0205921W WO03060111A2 WO 2003060111 A2 WO2003060111 A2 WO 2003060111A2 GB 0205921 W GB0205921 W GB 0205921W WO 03060111 A2 WO03060111 A2 WO 03060111A2
Authority
WO
WIPO (PCT)
Prior art keywords
raf
nucleic acid
mutation
mutant
sample
Prior art date
Application number
PCT/GB2002/005921
Other languages
English (en)
Other versions
WO2003060111A3 (fr
Inventor
Mike Stratton
Andy Futreal
Richard Wooster
Richard Malcolm Marais
Chris Marshall
Original Assignee
Catalyst Biomedica Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biomedica Limited filed Critical Catalyst Biomedica Limited
Priority to AU2002356323A priority Critical patent/AU2002356323A1/en
Publication of WO2003060111A2 publication Critical patent/WO2003060111A2/fr
Publication of WO2003060111A3 publication Critical patent/WO2003060111A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des mutations dans des produits du gène B-Raf. Les mutations décrites sont identifiées dans des tumeurs humaines d'origine naturelle. Ces mutations sont associées à des phénotypes cancéreux et peuvent être utilisées en tant que base pour le diagnostic du cancer, de cellules cancéreuses ou d'une prédisposition au cancer chez des êtres humains, et pour le développement de méthodes thérapeutiques contre le cancer.
PCT/GB2002/005921 2001-12-24 2002-12-24 Genes WO2003060111A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356323A AU2002356323A1 (en) 2001-12-24 2002-12-24 Cancer-specific mutants of b-raf genes and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34468401P 2001-12-24 2001-12-24
US60/344,684 2001-12-24

Publications (2)

Publication Number Publication Date
WO2003060111A2 true WO2003060111A2 (fr) 2003-07-24
WO2003060111A3 WO2003060111A3 (fr) 2004-02-26

Family

ID=23351558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005921 WO2003060111A2 (fr) 2001-12-24 2002-12-24 Genes

Country Status (2)

Country Link
AU (1) AU2002356323A1 (fr)
WO (1) WO2003060111A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 April 1993 (1993-04-27), SITHANANDAM, G. ET AL.: "Human B-raf mRNA, complete cds" XP002249539 retrieved from M95712 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179532 *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 9 April 1996 (1996-04-09), IKAWA, S. ET AL.: "Human B-raf oncogene mRNA, 3' end" XP002249540 retrieved from M21001 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179534 *
MACNICOL M C ET AL: "Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 FEB 2000, vol. 275, no. 6, 11 February 2000 (2000-02-11), pages 3803-3809, XP002249537 ISSN: 0021-9258 *
OKADA TOMOYO ET AL: "The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases." MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 9, 1999, pages 6057-6064, XP002249538 ISSN: 0270-7306 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
WO2003060111A3 (fr) 2004-02-26
AU2002356323A8 (en) 2003-07-30
AU2002356323A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
US8580497B2 (en) Methods for detection of the oncogenic T1796A B-Raf mutation
JP7186700B2 (ja) 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法
US20040096855A1 (en) Genes
DK2456889T3 (en) Markers of endometrial cancer
CA2676179C (fr) Variantes d'epissages specifiques metastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
AU2018209950A1 (en) Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) variants and uses thereof
WO2006096473A2 (fr) Identification de polynucleotides pour prevoir l'activite de composes qui interagissent avec et/ou modulent les proteine tyrosine kinases et/ou les voies des proteine tyrosine kinase dans les cellules du sein
CN116113712A (zh) 用于癌症的预后生物标志物
WO2003060111A2 (fr) Genes
EP2486154B1 (fr) Marqueurs de diagnostic et de pronostic du cancer
JP2006515515A (ja) 診断および治療スクリーニングに有用な増幅癌標的遺伝子
ES2362745T3 (es) Mutaciones en el gen b-raf.
CA2575462A1 (fr) Mutations dans des erb2 associee a des phenotypes cancereux
WO2008049022A2 (fr) Procédés de détection du cancer
US20080206248A1 (en) Mutations in ErbB2 associated with cancerous phenotypes
US20240076742A1 (en) Methods for improved cancer treatment
EP2767594A1 (fr) Signature de signalisation Wnt/ß-caténine dans le cancer
CN113943801A (zh) 生物标志物在制备或筛选结直肠癌诊断试剂中的用途
KR20150113561A (ko) 방광암 재발 진단 마커
Maxwell et al. Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP